The first preclinical study of a new Rice Univ.-developed anticancer technology found that a novel combination of existing clinical treatments can instantaneously detect and kill only cancer cells without harming surrounding normal organs. The research reports that Rice’s “quadrapeutics” technology was 17 times more efficient than conventional chemoradiation therapy against aggressive, drug-resistant head and neck tumors.
Biomedical engineering researchers have developed daisy-shaped, nanoscale structures that are made predominantly of anticancer drugs and are capable of introducing a “cocktail” of multiple drugs into cancer cells. The researchers are all part the joint biomedical engineering program at North Carolina State Univ. and the Univ. of North Carolina at Chapel Hill.
A pathway to the design of even more effective versions of the powerful anticancer drug Taxol has been opened with the most detailed look ever at the assembly and disassembly of microtubules, tiny fibers of tubulin protein that form the cytoskeletons of living cells and play a crucial role in mitosis.
Chemists at The Scripps Research Institute have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration for clinical trials in cancer patients. The new report, published in Angewandte Chemie, focuses on a compound called TIC10.
Photodynamic therapy (PDT) is an effective treatment for easily accessible tumors such as oral and skin cancer. But the procedure, which uses lasers to activate special drugs called photosensitizing agents, isn’t adept at fighting cancer deep inside the body. That could change because of a new technology that could bring PDT into areas of the body which were previously inaccessible.
Researchers have created a prototype system that uses a mathematical model to predict—and a portable inkjet technology to produce—precise medication dosages tailored for specific patients, an advance in personalized medicine that could improve drug effectiveness and reduce adverse reactions.
A comparatively new form of a medication for alcohol and opioid dependence that’s injected once a month instead of taken orally once a day appears to be significantly more effective than some other medications—because more patients actually continue the prescribed regimen. The findings offer support for a wider use of medications that may help reduce or prevent substance abuse and related hospital admissions.
In pharmaceutical production, identifying enzyme catalysts that help improve the speed and efficiency of the process can be a major boon. Figuring out exactly why a particular enzyme works so well is an altogether different quest. Take the cholesterol-lowering drug simvastatin.
The human body is full of proteins called enzymes that help nearly every function in the body. Scientists have been studying enzymes for decades in order to learn how they work and how to create better drugs and medical treatments for many ailments. Now, Univ. of Missouri researchers have completed a 3-D map of an enzyme called Proline utilization A (PutA).
Chemists in the College of Arts and Sciences at Syracuse Univ. have figured out how to control multiple bacterial behaviors—potentially good news for the treatment of infectious diseases and other bacteria-associated issues, without causing drug resistance.
Agilent Technologies Inc. has announced the signing of a memorandum of understanding with Seoul National Univ., Korea's top research university, on a new research center that will support the College of Pharmacy's New Drug Development Center. The collaboration will conduct drug metabolism studies, develop new compounds, study remedial effects and toxicity, assess pharmacokinetics, and conduct clinical tests for drugs.
Biomedical engineering researchers have developed an anti-cancer drug delivery method that essentially smuggles the drug into a cancer cell before triggering its release. The method can be likened to keeping a cancer-killing bomb and its detonator separate until they are inside a cancer cell, where they then combine to destroy the cell.
Massachusetts Institute of Technology researchers have devised a novel cancer treatment that destroys tumor cells by first disarming their defenses, then hitting them with a lethal dose of DNA damage. In studies with mice, the research team showed that this one-two punch, which relies on a nanoparticle that carries two drugs and releases them at different times, dramatically shrinks lung and breast tumors.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital. Four patients are still alive after more than two-and-a-half years and without additional treatment.
Patients who use medical marijuana for pain and other chronic symptoms can take an unwanted hit: Insurers don't cover the treatment, which costs as much as $1,000 a month. Once the drug of choice for hippies and rebellious teens, marijuana in recent years has gained more mainstream acceptance for its ability to boost appetite, dull pain and reduce seizures in everyone from epilepsy to cancer patients.
For HIV patients being treated with anti-AIDS medications, resistance to drug therapy regimens is commonplace. Often, patients develop resistance to first-line drug therapies, such as Tenofovir, and are forced to adopt more potent medications. Virologists at the Univ. of Missouri now are testing the next generation of medications that stop HIV from spreading, and are using a molecule related to flavor enhancers found in soy sauce.
Rice Univ. scientists have designed a tunable virus that works like a safe deposit box. It takes two keys to open it and release its therapeutic cargo. The Rice team developed an adeno-associated virus (AAV) that unlocks only in the presence of two selected proteases, enzymes that cut up other proteins for disposal. Because certain proteases are elevated at tumor sites, the viruses can be designed to target and destroy the cancer cells.
Northwestern Medicine scientists have newly identified a protein’s key role in cell and physiological aging and have developed—in collaboration with Tohoku Univ. in Japan—an experimental drug that inhibits the protein’s effect and prolonged the lifespan in a mouse model of accelerated aging. The rapidly aging mice fed the experimental drug lived more than four times longer than a control group.
Johns Hopkins Univ. biochemists have figured out what is needed to activate and sustain the virus-fighting activity of an enzyme found in CD4+ T cells, the human immune cells infected by HIV. The discovery could launch a more effective strategy for preventing the spread of HIV in the body with drugs targeting this enzyme, they say.
More than three decades after the eradication of smallpox, U.S. officials say it's still not time to destroy the last known stockpiles of the virus behind one of history's deadliest diseases. The world's health ministers meet later this month to debate, again, the fate of vials held under tight security in two laboratories—one in the U.S. and one in Russia.
In the fight against “superbugs,” scientists have discovered a class of agents that can make some of the most notorious strains vulnerable to the same antibiotics that they once handily shrugged off. The report on the promising agents called metallopolymers appears in the Journal of the American Chemical Society.
Federal health regulators are weighing the risks of permitting Merck to sell its prescription respiratory pill, Singulair, as an over-the-counter medicine for allergies. In a review posted online Wednesday, the Food and Drug Administration raised concerns that the drug could be used inappropriately by children or by patients with more serious conditions, like asthma.
Yale Univ.’s Michael Kinch spent his spare time in the last year creating a massive database that encompasses the entire history of drug development in the U.S. In a series of 20 articles scheduled to be published over the next year in Drug Discovery Today, Kinch mines the data and provides historical tidbits about the history of drug development and reveals trends on how—or whether—we will get new medicines in the future.
A Univ. of Michigan (U-M) startup developing drugs to target gene fusions that drive many common cancers such as breast, colon, prostate and lung has signed a research and license agreement with a California biopharmaceutical company. OncoFusion Therapeutics Inc., an oncology discovery and development company, was co-founded in 2012 by U-M profs. Arul Chinnaiyan and Shaomeng Wang based on discoveries from their campus laboratories.
Ten years of U.S. data suggest cholesterol-lowering statins are giving patients a license to pig out. Calorie and fat intake increased among statin users during the decade—an indication that many patients might be abandoning heart-healthy lifestyles and assuming that drugs alone will do the trick, the study authors said.